Palisade Bio, Inc. (PALI) News
Follow Palisade Bio, Inc. (PALI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Palisade Bio presents PALI-2108 data at ACG 2026
The company presented clinical, pharmacokinetic, pharmacodynamic and mechanistic data on PALI-2108 in ulcerative colitis and Crohn’s disease.
EQUITY | Oct 12, 2026, 12:05 PM UTC
L
Weekly Recap: PALI-2108 clearances and $125M cash, no long-term debt
Palisade Bio, Inc. (NASDAQ:PALI) won FDA and Health Canada clearances to begin ASCENTRA-UC and ASCENTRA-CD Phase II trials with readouts due 2027—2028, backed by about $125M cash and no long-term debt, while HC Wainwrigh
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
Palisade Bio, Inc. (PALI) Gains Health Canada CTA OK for Phase 2b UC Trial
Palisade Bio received Health Canada CTA clearance for ASCENTRA-UC, expanding its global Phase 2 trial of oral PALI-2108 in moderately to severely active ulcerative colitis. Primary 12-week induction results from ~204 pat
NEWS | Sep 23, 2026, 12:54 PM UTC
L
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis ex
NEWS | Sep 23, 2026, 12:53 PM UTC
L
PALI - Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
PALI - Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
NEWS | Sep 23, 2026, 12:45 PM UTC
L
HC Wainwright & Co. reiterates Buy rating on Palisade Bio, $7 price target
HC Wainwright & Co. reiterated their Buy rating on Palisade Bio's stock with a price target of $7.00.The price target implies an upside of 314.2% from the Sep 22 close of $1.69.Key takeaways from the analyst notePositive
EQUITY | Sep 23, 2026, 11:12 AM UTC
L
PALI - Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
PALI - Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
REGULATION | Sep 22, 2026, 12:44 PM UTC
L
PALI - Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
PALI - Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
NEWS | Sep 21, 2026, 01:00 PM UTC
L
Palisade Bio to participate in upcoming investor conferences
Palisade Bio (PALI) says it will participate in upcoming investor conferences.
EQUITY | Sep 03, 2026, 01:00 PM UTC
L
PALI Initiated Outperform W/$8.00 PT at Oppenheimer
PALI Initiated Outperform W/$8.00 PT at Oppenheimer
EQUITY | Jul 23, 2026, 11:55 AM UTC
L
PALI new Outperform W/ $8 PT @ OPCO
PALI new Outperform W/ $8 PT @ OPCO
EQUITY | Jul 23, 2026, 11:32 AM UTC